Source: https://www.vair-journal.com/jour/article/view/121
Timestamp: 2019-04-26 13:49:41+00:00

Document:
1. Ломиворотов В. В., Шмырев В. А., Ефремов С. М. и др. Динамика содержания тропонина I в сыворотке крови взрослых пациентов с приобретенными пороками сердца, оперированных в условиях нормотермического и гипотермического искусственного кровообращения // Вестн. анестезиол. и реаниматол. – 2014. – Т. 11, № 1. – С. 3–10.
2. Тимофеев А. Б., Щеголев А. В., Рыжман Н. Н. Современные подходы к терапии сердечной недостаточности при остром инфаркте миокарда // Вестн. анестезиол. и реаниматол. – 2014. – Т. 11, № 1. – С. 68–75.
3. Balestrino M., Sarocchi M., Adriano E. et al. Potential of creatine or phosphocreatine supplementation in cerebrovascular disease and in ischemic heart disease // Amino Acids. 2016. Jan 21. [Epub ahead of print].
4. Bottomley P. A., Panjrath G. S., Lai S. et al. Metabolic rates of ATP transfer through creatine kinase (CK Flux) predict clinical heart failure events and death // Sci. Transl. Med. – 2013. – Vol. 215, № 5. – P. 215re3.
5. Braunwald E., Kloner R. A. The stunned myocardium: prolonged, postischemic ventricular dysfunction // Circulation. – 1982. – Vol. 66, № 6. – P. 1146–1149.
6. Chambers D. J., Haire K., Morley N. et al. St. Thomas’ hospital cardioplegia: enhanced protection with exogenous creatine phosphate // Ann. Thorac. Surg – 1996. – Vol. 61, № 6. – P. 67–75.
7. Cleland J. G., Daubert J. C., Erdmann E. et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure // N. Engl. J. Med. – 2005. – Vol. 352, № 15. – P. 1539–1549.
8. Cossolini M., Sonzogni V., Di Dedda G. et al. Paediatric cold heart surgery: experience with creatine phosphate added to cardioplegic solution. In D’Alessandro LC (ed). Heart Surgery. Roma: Casa Editrice Scientifica Internazionale. – 1993. – P. 442–443.
9. Dayer M., Cowie M. R. Heart failure: diagnosis and healthcare burden // Clin. Med. – 2004. – Vol. 4, № 1. – P. 13–18.
10. Ferraro S., Codella C., Palumbo F. et al. Hemodynamic effects of creatine phosphate in patients with congestive heart failure: a double-blind comparison trial versus placebo // Clin. Cardiol. – 1996. – Vol. 19, № 9. – P. 699–703.
11. Gebhard M. M. Myocardial protection and ischemia tolerance of the globally ischemia heart // Thorac. Cardiovasc. Surg. – 1990. – Vol. 38, № 2. – P. 55–59.
12. Grazioli I., Strumia E. Terapia con creatina fosfato nel paziente con insufficienza cardiaca in fase di scompenso: studio policentrico // G. Ital. Ric. Clin. Ter. – 1989. – № 10. – P. 39–45.
13. Hearse J. Ischemia at the crossroads? // Cardiovasc. Drugs Ther. – 1988. – Vol. 2, № 1. – P. 9–15.
14. Horjus D. L., Oudman I., van Montfrans G. A. et al. Creatine and creatine analogues in hypertension and cardiovascular disease // Cochrane Database Syst. Rev. – 2011. – № 11. – P. CD005184.
15. Iosseliani D. G., Koledinsky A. G., Kuchkina N. V. Does intracoronary injection of phosphocreatine prevent myocardial reperfusion injury following angioplasty of infarct-related artery in acute-stage of myocardial infarction? // J. Interv. Cardiol. – 2004. – № 6. – P. 10–14.
16. Jernberg T., Johanson P., Held C. et al. Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction // JAMA. – 2011. – Vol. 305, № 16. – P. 1677–1684.
17. Kolwicz S. C., Purohit S., Tian R. Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes // Circ. Res. – 2013. – Vol. 113, № 5. – P. 603–616.
18. Landoni G., Zangrillo A., Lomivorotov V. V. et al. Cardiac protection with phosphocreatine: a meta-analysis // Interact. Cardiovasc. Thorac. Surg. – 2016. Jun 17. [Epub ahead of print].
19. Li T., Wang N., Zhao M. Neuroprotective effect of phosphocreatine on focal cerebral ischemia-reperfusion injury // J. Biomed. Biotechnol. – 2012. – № 2012. – P. 168756.
20. Lomivorotov V. V., Boboshko V. A., Chernyavsky A. M. et al. Preventive IABP use of levosimendan infusion in coronary patients with low left ventricular ejection fraction (< 35%) // Patologiya krovoobrashcheniya I kardiokhirurgiya = Circulation Pathology and Cardiac Surgery. – 2011. – № 2. – P. 49–54.
21. Lomivorotov V. V., Boboshko V. A., Efremov S. M. et al. Levosimendan versus an intra-aortic balloon pump in high-risk cardiac patients // J. Cardiothorac. Vasc. Anesth. – 2012. – Vol. 26, № 4. – P. 596–603.
22. Lomivorotov V. V., Efremov S. M., Shmirev V. A. et al. Glutamine is cardioprotective in patients with ischemic heart disease following cardiopulmonary bypass // Heart Surg. Forum. – 2011. – Vol. 14, № 6. – P. E384–E388.
23. Lygate C. A., Bohl S., ten Hove M. et al. Moderate elevation of intracellular creatine by targeting the creatine transporter protects mice from acute myocardial infarction // Cardiovasc. Res. – 2012. – Vol. 96, № 3. – P. 466–475.
24. Mastroroberto P., Di Tommaso L., Chello M. et al. Creatine phosphate protection of the ischemic myocardium during cardiac surgery // Current Therapeutic Research. – 1992. – № 51. – P. 37–45.
25. Melrose D. G., Dreyer B., Bentall H. H. et al. Elective cardiac arrest // Lancet. – 1955. – № 269. – P. 21–22.
26. Neubauer S., Krahe T., Schindler R. et al. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure // Circulation. – 1992. – Vol. 86, № 6. – P. 1810–1818.
27. Neubauer S. The failing heart – an engine out of fuel // N. Engl. J. Med. – 2007. – Vol. 356, № 11. – P. 1140–1151.
28. Opie L. H. Cardiac metabolism–emergence, decline, and resurgence. Part II // Cardiovasc. Res. – 1992. – Vol. 26, № 9. – P. 817–830.
29. Perepech N. B., Nedoshivin A. O., Nesterova I. V. Neoton and thrombolytic therapy of myocardial infarction // Ter. Arkh. – 2001. – Vol. 73, № 9. – P. 50–55.
30. Pitt B., Zannad F., Remme W. J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure // N. Engl. J. Med. – 1999. – Vol. 341, № 10. – P. 709–717.
31. Prabhakar G., Vona-Davis L., Murray D. et al. Phosphocreatine restores high-energy phosphates in ischemic myocardium: implication for off-pump cardiac revascularization // J. Am. Coll. Surg. – 2003. – Vol. 197, № 5. – P. 786–791.
32. Robinson L.A., Braimbridge M.V., Hearse D.J. Creatine phosphate: an additive myocardial protective and antiarrhythmic agent in cardioplegia // J. Thorac. Cardiovasc. Surg. – 1984. – Vol. 87, № 2. – P. 190–200.
33. Ruda M. Y., Samarenko M. B., Afonskaya N. I. et al. Reduction of ventricular arrhythmias by phosphocreatine (Neoton) in patients with acute myocardial infarction // Am. Heart J. – 1988. – Vol. 116, № 2. – Pt. 1. – P. 393–397.
34. Schaper J., Meiser E., Stämmler G. Ultrastructural morphometric analysis of myocardium from dogs, rats, hamsters, mice, and from human hearts // Circ. Res. – 1985. – Vol. 56, № 3. – P. 377–391.
35. Semenovsky M. L., Shumakov V. I., Sharov V. G. et al. Protection of ischemic myocardium by exogenous phosphocreatine. II. Clinical, ultrastructural, and biochemical evaluations // J. Thorac. Cardiovasc. Surg. – 1987. – Vol. 94, № 5. – P. 762–769.
36. Sharov V. G., Afonskaya N. I., Ruda M. Y. et al. Protection of ischemic myocardium by exogenous phosphocreatine (neoton): pharmacokinetics of phosphocreatine, reduction of infarct size, stabilization of sarcolemma of ischemic cardiomyocytes, and antithrombotic action // Biochem. Med. Metab. Biol. – 1986. – Vol. 35, № 1. – P. 101–114.
37. Shen W., Spindler M., Higgins M. A. et al. The fall in creatine levels and creatine kinase isozyme changes in the failing heart are reversible: complex post-transcriptional regulation of the components of the CK system // J. Mol. Cell. Cardiol. – 2005. – Vol. 39, № 3. – P. 537–544.
38. Smilari L., La Mela C., Santagati A. Study of left ventricular function in ischemic cardiomyopathies before and after phosphocreatine infusion. echocardiographic study // Current Therapeutic Research. – 1987. – Vol. 41. – P. 557–567.
39. Spindler M., Meyer K., Stromer H. et al. Creatine kinase deficient hearts exhibit increased susceptibility to ischemia-reperfusion injury and impaired calcium homeostasis // Am. J. Physiol. Heart. Circ. Physiol. – 2004. – Vol. 287, № 3. – P. H1039–H1045.
40. Strumia E., Pelliccia F., D’Ambrosio G. Creatine phosphate: pharmacological and clinical perspectives // Adv. Ther. – 2012. – Vol. 29, № 2. – P. 99–123.
41. Tang L. H., Xia Z. Y., Zhao B. et al. Phosphocreatine preconditioning attenuates apoptosis in ischemia-reperfusion injury of rat brain // J. Biomed. Biotechnol. – 2011. – № 2011. – P. 107091.
42. Tani M., Neely J. R. Mechanisms of reperfusion injury by low Ca2+ and/or high K+ // Am. J. Physiol. – 1990. – Vol. 258, № 4. Pt 2. – P. H1025–H1031.
43. Tani M., Neely J.R. Role of intracellular Na+ in Ca++ overload and depressed revovery of ventricular function of pererfused ischemic rat hearts: possible of H+/Na+ exchange // Circ. Res. – 1989. – Vol. 4, № 65. – P. 1045–1056.
44. ten Hove M., Lygate C. A., Fischer A. et al. Reduced inotropic reserve and Increased susceptibility to cardiac ischemia/reperfusion injury in phosphocreatine-deficient guanidinoacetate-N-methyltransferase-knockout mice // Circulation. – 2005. – Vol. 111, № 19. – P. 2477–2485.
45. Thorelius J., Thelin S., Ronquist G. et al. Biochemical and functional effects of creatine phosphate in cardioplegic solution during aortic valve surgery – a clinical study // Thorac. Cardiovasc. Surg. – 1992. – Vol. 40, № 1. – P. 10–13.
46. Tokarska-Schlattner M., Epand R. F., Meiler F. et al. Phosphocreatine interacts with phospholipids, affects membrane properties and exerts membrane-protective effects // PLoS One. – 2012. – Vol. 7, № 8. – P. e43178.
47. VanBenthuysen K. M., McMurtry I. F., Horwitz L. D. Reperfusion after acute coronary occlusion in dogs impairs endothelium-dependent relaxation to acetylcholine and augments contractile reactivity in vitro // J. Clin. Invest. – 1987. – Vol. 79, № 1. – P. 265–274.
48. Vinten-Johansen J., Johnston W. E., Mills S. A. Reperfusion injury after temporary coronary occlusion // J. Thorac. Cardiovasc. Surg. – 1988. – Vol. 95, № 6. – P. 960–968.
49. Woo Y. J., Grand T. J., Zentko S. et al. Creatine phosphate administration preserves myocardial function in a model of off-pump coronary revascularization // J. Cardiovasc. Surg. – 2005. – Vol. 46, № 3. – P. 297–305.
50. Wyss M., Kaddurah-Daouk R. Creatine and creatinine metabolism // Physiol. Rev. – 2000. – Vol. 80, № 3. – P. 1107–1213.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.